Funding for this research was provided by:
Horizon 2020 Framework Programme (856620)
Jane ja Aatos Erkon Säätiö
Sigrid Juselius Foundation
The Finnish Society of Sciences And Letters
Received: 2 May 2020
Accepted: 21 July 2020
First Online: 31 July 2020
Consent for publication
: Not applicable.
: A.H. is a shareholder in Targovax ASA. A.H. is an employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.